| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Third Quarter and Full Year 2024 Guidance
| Third Quarter 2024 | Full Year 2024 | ||
| Revenue | $113 million to $114 million | $442 million to $444 million | |
| Year-over-Year Growth % | ~19% to 20% | ~20% to 21% | |
| Adjusted EBITDA | $36 million | $140 million | |
| Adjusted EBITDA Margin % | ~32% | ~32% | |
| Total Equity-based compensation expense and related payroll taxes | ~$106 million | ||
| Depreciation and Amortization | ~$12 million | ||
| Non-GAAP effective tax rate | 25 % | ||
| Diluted non-GAAP share count | ~258 million |
Certain components of the guidance given above are provided on a non-GAAP basis only without providing a reconciliation to guidance provided on a GAAP basis. Information is presented in this manner because the preparation of such a reconciliation could not be accomplished without "unreasonable efforts." The Company does not have access to certain information that would be necessary to provide such a reconciliation, including non-recurring items that are not indicative of the Company's ongoing operations. The Company does not believe that this information is likely to be significant to an assessment of the Company's ongoing operations.
Posted In: CWAN
